Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers Eight U.S. Locations, December 2020 March 2021
Mark G. Thompson, Jefferey L. Burgess, Allison L. Naleway, Harmony L. Tyner, Sarang K. Yoon, Jennifer Meece, Lauren E.W. Olsho, Alberto J. Caban-Martinez, Ashley Fowlkes, Karen Lutrick, Jennifer L. Kuntz, Kayan Dunnigan, Marilyn J. Odean, Kurt T. Hegmann, Elisha Stefanski, Laura J. Edwards, Natasha Schaefer-Solle, Lauren Grant, Katherine Ellingson, Holly C. GroomTnelda Zunie, Matthew S. Thiese, Lynn Ivacic, Meredith G. Wesley, Julie Mayo Lamberte, Xiaoxiao Sun, Michael E. Smith, Andrew L. Phillips, Kimberly D. Groover, Young M. Yoo, Joe Gerald, Rachel T. Brown, Meghan K. Herring, Gregory Joseph, Shawn Beitel, Tyler C. Morrill, Josephine Mak, Patrick Rivers, Katherine M. Harris, Danielle R. Hunt, Melissa L. Arvay, Preeta Kutty, Alicia M. Fry, Manjusha Gaglani
Dive into the research topics of 'Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers Eight U.S. Locations, December 2020 March 2021'. Together they form a unique fingerprint.